It is peptide-derived rather than a plain peptide — a modified compound based on an angiotensin IV fragment. That matters analytically, because a modified molecule is characterised differently from a straight sequence.

What research tradition does Pinealon come from?

The Russian peptide-bioregulator programme that also produced Epitalon and Cartalax. Its literature is concentrated there, with limited independent replication.

Which has stronger evidence?

Neither has replicated human evidence. Dihexa's work is preclinical and concentrated around a specific academic line; Pinealon's sits within one research tradition. Both should be read with that in mind.

Dihexa vs Pinealon — Western academic work against a Russian bioregulator

5 min readUpdated 2026-08-27

Dihexa is a compound derived from angiotensin IV, developed in Western academic research and studied in connection with hepatocyte growth factor signalling. Pinealon is a three-amino-acid bioregulator from the Russian peptide programme. Both carry the cognitive-research label; they share no structure, no mechanism and no literature.

The nootropic label puts these together. Their research worlds barely touch, and that is the substance of the comparison.

Two research worlds

Comparison
	Dihexa	Pinealon
Derived from	Angiotensin IV	Russian bioregulator programme
Setting	Western academic research	Single research tradition
Associated mechanism	Hepatocyte growth factor signalling	Neuroprotective models
Evidence	Preclinical, narrow	Preclinical, narrow

Neither has what the label implies

"Cognitive" or "nootropic" implies a demonstrated effect on human cognition. Neither compound has replicated human evidence supporting that, and a category label is not a finding. The honest description of both is early-stage research material.

The compounds discussed here

Dihexa Pinealon

Not sure where to startAnswer four questions and see what the research points to →

Go deeper

Choosing a US peptide supplier for a clinic or store

Frequently asked questions

Is Dihexa a peptide?: It is peptide-derived rather than a plain peptide — a modified compound based on an angiotensin IV fragment. That matters analytically, because a modified molecule is characterised differently from a straight sequence.
What research tradition does Pinealon come from?: The Russian peptide-bioregulator programme that also produced Epitalon and Cartalax. Its literature is concentrated there, with limited independent replication.
Which has stronger evidence?: Neither has replicated human evidence. Dihexa's work is preclinical and concentrated around a specific academic line; Pinealon's sits within one research tradition. Both should be read with that in mind.

References

Primary literature for the compounds above. Links open the record on PubMed.

The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases Wright JW, et al. Prog Neurobiol. 2015. PMID 25455861 → · summary
The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system Benoist CC, et al. J Pharmacol Exp Ther. 2014. PMID 25187433 → · summary